Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.65 |
| ▸ | CLK2 | P49760 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.65 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.65 |
| ▸ | MTOR | P42345 | 2/20 | 0.63 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 3/20 | 0.62 |
| ▸ | GSK3B | P49841 | 4/20 | 0.56 |
| ▸ | CDK2 | P24941 | 3/20 | 0.56 |
| ▸ | CDK4 | P11802 | 2/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | CCND3 | P30281 | 1/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.56 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.53 |
| ▸ | CTSC | P53634 | 3/20 | 0.52 |
| ▸ | IDH2 | P48735 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27116471 | 0.87 | CLK1 (0.66) | CLK1CLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL4901590 | 0.86 | ABL1 (0.67) | CLK1CLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL2328646 | 0.86 | CLK1 (0.65) | CLK1CLK2DYRK1ACLK4DYRK1B | |
| Nitric Acid SCHEMBL5734022 | 0.84 | CLK1 (0.49) | CLK1CLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL2329332 | 0.84 | KDM4E (0.58) | CLK1CLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL3513778 | 0.84 | CAMK2D (0.73) | MTORSMG1CDK2CDK4CCNA2 | |
| SCHEMBL2113984 | 0.83 | AURKA (0.77) | AURKACTSCIDH2KDM4E | |
| SCHEMBL25336406 | 0.83 | CAMK2D (0.69) | CLK1CLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL30554563 | 0.83 | CAMK2D (0.69) | CLK1CLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL27115596 | 0.83 | SYK (0.65) | CLK1CLK2DYRK1ACLK4DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0672042-B1 | PHARMACOLOGICALLY ACTIVE PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2006-05-03 | — | — | EP | claimed |
| US-5705502-A | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | claimed |
| EP-0672042-A1 | PHARMACOLOGICALLY ACTIVE PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1995-09-20 | — | — | EP | claimed |
| WO-1995009851-A1 | PHARMACOLOGICALLY ACTIVE PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | claimed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | disclosed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
| EP-0672041-B1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| WO-1999035140-A1 | PYRIDINYLPYRIMIDINE AMINES AS IMMUNOGLOBULINE E (IgE) SYNTHESIS INHIBITORS | NOVARTIS AG (CH) | 1999-07-15 | — | — | WO | disclosed |
| US-5728708-A | ANTITUMOR AGENTS | NOVARTIS CORPORATION (US) | 1998-03-17 | — | — | US | disclosed |
| EP-0672041-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995009853-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | CLK1 3275/4885CLK2 2309/4885DYRK1A 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.